We tested the hypothesis that antagonism of progesterone receptor (PR) in newborn rats alters carotid body and respiratory responses to hypoxia and nicotinic receptor agonists. Rats were treated with the PR antagonist mifepristone (daily oral gavage 40 μg/g/d) or vehicle between postnatal days 3 and 15. In 11-14-day-old rats, we used in vitro carotid body/carotid sinus nerve preparation and whole body plethysmography to assess the carotid body and ventilatory responses to hypoxia (65 mmHg in vitro, 10% O2 in vivo) and to nicotinic receptor agonists (as an excitatory modulator of carotid body activity-nicotine 100 μM for in vitro studies, and epibatidine 5 μg/kg, i.p., which mainly acts on peripheral nicotinic receptors, for in vivo studies). The carotid body responses to hypoxia and nicotine were drastically reduced by mifepristone. Compared with vehicle, mifepristone-treated rats had a reduced body weight. The ventilatory response to epibatidine was attenuated; however, the hypoxic ventilatory response was similar between vehicle and mifepristone-treated pups. Immunohistochemical staining revealed that mifepristone treatment did not change carotid body morphology. We conclude that PR activity is a critical factor ensuring proper carotid body function in newborn rats.
Keywordscarotid sinus nerve; whole-body plethysmography; hypoxia; nicotine receptor agonist; progesterone receptor antagonist; newborn Progesterone is a respiratory stimulant that acts both on the central nervous system (CNS) and on peripheral chemoreceptors to enhance resting minute ventilation (Bayliss et al., 1987), the hypoxic ventilatory response (Joseph et al., 2002), and the carotid sinus nerve response to hypoxia (Hannhart et al., 1990). These effects of progesterone are well described in adults and also occur in newborn rats in which chronic progesterone exposure enhances the hypoxic ventilatory response and reduces apnea frequency under normoxia or hypoxia (Lefter et al., 2007(Lefter et al., , 2008. This has potential far-reaching implications because progesterone-based hormone replacement therapy reduces the occurrence of sleep apneas in